This longitudinal study examined the relationship between 2-year change in white matter hyperintense lesion (WML) volume and polymorphisms in genes coding for the angiotensin-II type 1 and type 2 receptors, AGTR1 A1166C and AGTR2 C3123A, respectively. 137 depressed and 94 non-depressed participants aged X60 years were enrolled. Standard clinical evaluations were performed on all participants and blood samples obtained for genotyping. 1.5-T MRI (magnetic resonance imaging) data were obtained at baseline and approximately 2 years later. These scans were processed using a semi-automated segmentation process, which allowed for the calculation of WML volume at each time point. Statistical models were tested for the relationship between change in WML volume and genotype, while also controlling for age, sex, diagnostic strata, baseline WML volume and comorbid cerebrovascular risk factors. In men, AGTR1 1166A allele homozygotes exhibited significantly less change in WML volume than 1166C carriers. We also found that men reporting hypertension (HTN) with the AGTR2 3123C allele exhibit less change in WML volume than hypertensive men with the 3123A allele, or men without HTN. There were no significant relationships between these polymorphisms and change in WML volume in women. No significant gene-gene or gene-depression interactions were observed. Our results parallel earlier observed gender differences of the relationship between other renin-angiotensin system polymorphisms and HTN. Further work is needed to determine whether these observed relationships are secondary to polymorphisms affecting response to antihypertensive medication, and whether antihypertensive medications can slow WML progression and lower the risk of morbidity associated with WMLs.
Introduction
Cerebral hyperintensities are the regions of increased signal intensity observed on T2-weighted magnetic resonance imaging (MRI), which are associated not only with ischemia and advanced age, 1 but also with cognitive impairment, 1 motor disability 2 and depression. 3 They are often described as subcortical ischemic disease and share risk factors with cerebrovascular disease. [1] [2] [3] [4] Little is known about the genes associated with complex multifactorial ischemic disease of the brain. There are likely many alleles across multiple pathways, each a with small effect size, contributing to ischemia risk. 5 The genes in the renin-angiotensin system (RAS) are among such candidates. The RAS regulates blood pressure and fluid homeostasis primarily through the effect of angiotensin II on two major receptor types, AT 1 and AT 2 . Angiotensin II acts peripherally and centrally, in which it exhibits pressor effects and regulates the secretion of the antidiuretic hormone. In addition, stimulation of AT 2 receptors may potentiate the expression of methyl methanesulfonate sensitive 2, a neuroprotective factor that may be protective against cerebral ischemia. 6 Polymorphisms of the genes coding for these receptors may modulate the effect of angiotensin II. The C allele variant of the A1166C single nucleotide polymorphism (SNP) of the AGTR1 gene is associated with hypertension (HTN), 7 cardiac disease 7 and ischemic stroke. 7, 8 The X chromosome-linked AGTR2 gene is less well-studied and its location raises the possibility of sex differences in gene effects. The A allele variant of the AGTR2 C3123A polymorphism is associated with cardiac disease 9 and the response of blood pressure to salt intake in men. 10 We examined the relationship between these polymorphisms and change in white matter hyperintense lesion (WML) volume over a 2-year period in a cohort of depressed and non-depressed older participants. We hypothesized that the AGTR1 1166C allele and the AGTR2 3123A allele would be associated with greater change in WML volume. As exploratory aims, we tested for gene-gene and genedemographic interactions (including gene-diagnosis and gene-sex interactions) affecting WML volume change.
Methods

Sample
The participants were aged X60 years and took part in the NIMH-sponsored Conte Center for the Neuroscience of Depression at Duke University Medical Center. Depressed participants met DSM-IV criteria for Major Depressive Disorder at enrollment on the basis of the NIMH Diagnostic Interview Schedule 11 and by clinical interview. Exclusion criteria included (1) another major psychiatric illness; (2) history of substance abuse or dependence; (3) primary neurological illness, including dementia; and (4) MRI contraindications. The participants were recruited primarily through clinical referrals, and also through limited advertising and self-referral.
Community-dwelling comparison participants were recruited from Duke's Aging Center Subject Registry. Eligible comparison participants had a nonfocal neurological examination, no self-report of neurological or psychiatric illness, no evidence of a psychiatric diagnosis on the basis of the Diagnostic Interview Schedule and no contraindication to MRI. The study was approved by the Duke University Medical Center Institutional Review Board and all participants provided written informed consent.
We have earlier published studies examining longitudinal change in hyperintense lesion volume in this sample. [12] [13] [14] This study was restricted to those participants with both longitudinal neuroimaging data and genetic polymorphism data, and further restricted to Caucasian participants as others have reported racial differences in AGTR1 A1166C allele frequency. 7 341 participants had genetic data. Of those, 290 were Caucasian and only 231 had longitudinal MRI data. When compared with Caucasian participants who remained in the study, participants without follow-up MRI data were significantly older, less educated, with lower Mini Mental State Examination scores and higher WML volumes (data not shown). Depressed participants were more likely to not have follow-up MRI data but there were no differences based on sex or AGTR1 or AGTR2 genotype.
Clinical assessments and antidepressant treatment
Participants completed a self-report questionnaire used in the NIMH Catchment Area Program, 15 which assessed demographic factors and the presence or absence of several medical conditions, including HTN, diabetes mellitus and heart disease. In the depressed population, the clinician-scored Montgomery-Asberg Depression Rating Scale 16 was used to measure depression severity.
Participants were excluded if they had a diagnosis of dementia at enrollment. The majority of participants had Mini Mental State Examination 17 scores above 24; some severely depressed individuals had scores below 25. These participants were followed through an acute 3-month treatment phase; if the scores remained below 25, they were removed from the study.
Depressed participants were treated over the course of the study period according to the Duke Somatic Treatment Algorithm for Geriatric Depression. 18 This algorithm mimics 'real world' treatment options rather than adhering to a rigid clinical trial design, by providing a stepwise treatment approach while accounting for past treatments and depression severity. All marketed antidepressants are allowed, and there are provisions for lithium augmentation and electroconvulsive therapy.
MRI acquisition
Participants were imaged approximately 2 years apart (mean 727.1 days, s.d. = 53.9 days, range 462-892 days) using a 1.5-T whole-body MRI system (Signa, GE Medical Systems, Milwaukee, WI, USA) with the standard head (volumetric) radiofrequency coil. A dual-echo fast spin-echo acquisition was obtained in the axial plane. The pulse sequence parameters are, repetition time = 4000 ms, echo time = 30, 135 ms, 32 KHz ( ± 16 KHz) full imaging bandwidth, echo train length = 16, a 256 Â 256 matrix, 3-mm section thickness, 1 excitation and a 20-cm field of view. The images were acquired in two separate acquisitions with a 3-mm gap between sections for each acquisition. The second acquisition was offset by 3 mm from the first so that the resulting data set consisted of contiguous sections with no gap.
Magnetic resonance image analysis
The segmentation protocol has been described earlier 19 and uses a modified version of MrX software (GE Corporate Research and Development, Schenectady, NY, USA), originally modified by Brigham and Women's Hospital (Boston, MA, USA). 20 . This semiautomated method uses multiple MR contrasts to identify tissue classifications through a 'seeding' process, wherein a trained analyst manually selected pixels in each tissue type to be identified. Lesion areas were selected on the basis of a set of explicit rules developed from neuroanatomical guidelines and consultation with a neuroradiologist. Both periventricular and deep white matter lesions were combined to provide a WML measure. Reliability was established by repeated measurements. Intraclass correlation coefficients were: left cerebral WMLs = 0.988, and right cerebral WMLs = 0.994.
Genotyping
Single nucleotide polymorphism genotyping was performed by TaqMan, using 'Assays-on-Demand' SNP genotyping products (Applied Biosystems, Foster City, CA, USA). For all assays, quality control measures were applied, including genotyping a series of blinded duplicate samples and Centre d'Etude du Polymorphism Human controls. The genotypes of all duplicate samples had to match 100% for the assay to pass quality control. Further, we required that each assay achieve 95% efficiency (the genotypes of at least 95% of the samples could be called with certainty) before statistical analysis. PCR was performed on the ABI 9700 dual 384-well GeneAmp PCR system and genotypes analyzed using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). Each reaction contained 2.7 ng of total genomic DNA, which had been extracted from whole blood using the Puregene method by Gentra Systems (Minneapolis, PA, USA).
Analytic plan
We performed initial screening comparisons of WML volume between the AGTR1 (rs5186) and AGTR2 (rs2148582) SNPs, as well as two SNPs in the gene coding for angiotensinogen (rs11568020 and rs2148582). As we found no signal for the angiotensinogen SNPs, we did not pursue further analyses. For the AGTR1 A1166C polymorphism, we dichotomized participants into A allele homozygotes and C allele carriers, as others have used this strategy. 21 For the X-linked AGTR2 C3123A polymorphism, we examined men (A or C genotype) and women (A/A, A/C or C/C) separately. There was no precedent to dichotomize women based on genotype, nor was one genotype under-represented.
We tested for group differences in demographic measures and unadjusted WML measures between diagnostic strata (depressed or non-depressed) and genotype groups. For dichotomous group comparisons, continuous variables were examined using twotailed pooled t-tests or the Satterthwaite t-test for unequal variances. For the trichotomous AGTR2 genotype groups in women, we used ANCOVA (analysis of covariance) to test for differences in continuous variables. w 2 -tables were used for categorical variables, or Fisher's exact test for low cell counts.
To examine the relationship between the AGTR1 and AGTR2 polymorphisms with change in WML volume, general linear models were created using the PROC GLM function in SAS 9.1 (Cary, NC, USA) and reduced to parsimonious models using backwards regression. The backwards regression was performed manually, removing independent variables or interaction terms one at a time on the basis of the variable that had the highest P-value, then rerunning the model until the only covariates remaining were those that were significantly related to change in lesion volume at P < 0.05 or those a priori designated to be retained. We first examined AGTR1 in all participants. After reaching a final model for WML volume and AGTR1, we separated the sample into men and women, added AGTR2 genotype and AGTR2 interactions to the models, and continued the backwards regression in each sex.
For the first model, WML volume change was the dependent variable, whereas diagnostic strata and AGTR1 genotype were independent variables to be retained. We additionally designated HTN to be retained in the model, as univariate analyses revealed difference in the HTN frequency between women with different AGTR2 genotypes, thereby requiring this variable for later AGTR2 analyses. Other independent variables included baseline lesion volume, time between MRI scans, age, sex and presence of diabetes and heart disease. We also included an interaction between AGTR1 and diagnosis, and an interaction between AGTR1 and sex. We next split the sample on the basis of sex, removed variables related to sex, and added AGTR2 genotype and an AGTR2-HTN interaction term. We planned to retain diagnostic strata, AGTR1 and AGTR2 genotypes in these models. After determining the final model for each sex, we tested for group differences between genotypes or interactions terms by examining adjusted predicted lesion volumes calculated using the least squares means procedure.
We validated our final models derived through backwards manual regression using bootstrapping. 22 This involves repeatedly created random samples with replacement from the original sample, in which data for a given participant may be used more than once for each resample. We used PROC REG to perform automated backwards stepwise regression of the full model for each resample. This resampling was repeated five times for each model, and we examined each resampled model to determine how often variables that were significant in the manually determined parsimonious model were present in the resampled models.
Results
Sample characteristics
The sample consisted of 137 depressed and 94 non-depressed older individuals ( Table 1 ). The nondepressed strata had a significantly higher level of education, a greater representation by women and a longer time between MRI scans, whereas the depressed strata included a higher percentage of participants reporting HTN.
The AGTR1 A1166C polymorphism did not deviate from Hardy-Weinberg Equilibrium in either depressed (w 2 = 2.44, 1 df, P = 0.1185) or non-depressed participants (w 2 = 1.13, 1 df, P = 0.2869). There were no significant differences in A1166C allele frequency between diagnostic strata, nor were there significant differences in demographics between AGTR1 A/A and C allele carrier cohorts ( Supplementary Table S1 ). C allele carriers exhibited a significantly greater increase in WML volume over the study period ( Table 2) .
As the AGTR2 gene is X-linked, we tested for deviation from Hardy-Weinberg Equilibrium in women only; we found no deviation in the depressed population (w 2 = 2.08, 1 df, P = 0.1489); however, the non-depressed female population did exhibit deviation from Hardy-Weinberg Equilibrium (w 2 = 6.19, 1 df, P = 0.0129). There was no difference in AGTR2 C3123A allele frequency between diagnostic strata, nor were there significant differences in demographics between the genotypes ( Supplementary  Tables S2 and S3 ) except for HTN being less frequent in C allele homozygous women (12.8%, 6/47) than in those carrying A alleles (A/C: 32.8%, 20/61; Abbreviations: ANCOVA, analysis of covariance; WML, white matter hyperintense lesion. Lesion volumes presented in milliliters as mean (s.d.) and analyzed used the Satterthwaite t-test due to unequal variances for the AGTR1 analyses and the AGTR2 analyses in men. ANCOVA was used for AGTR2 analyses in women, as genotype was three-tiered.
A/A: 34.0%, 16/47; w 2 = 7.03, 2 df, P = 0.0297). There were no significant differences between AGTR2 genotypes in the unadjusted WML measures ( Table 2) .
Multivariate analyses
The final model examining the relationship between the AGTR1 A1166C polymorphism and change in WML volume is shown in Table 3 . When validated through bootstrapping, the significant variables in this model (AGTR1 genotype, age, baseline WML volume and the AGTR1-sex interaction) appeared in all of the bootstrapped models. The predicted values for the AGTR1-sex interaction showed that men who were A/A homozygotes exhibited significantly less change in WML volume (0.6 ml) when compared with male C allele carriers (2.5 ml, P = 0.0018) or female C allele carriers (1.8 ml, P = 0.0141). The difference between male and female A/A homozygotes (1.4 ml) was not statistically significant (P = 0.0996), nor was the difference between male and female C allele carriers (P = 0.2340). We next added AGTR2 genotype. In the female cohort, we found that neither AGTR1 nor AGTR2 genotype was significantly associated with change in WML volume, and the AGTR2 by HTN interaction term was removed from the model by backwards regression (Table 4 ). In the male cohort, AGTR1 continued to be significantly associated with WML volume change, as was the HTN by AGTR2 interaction term (Table 4 ). This model was validated through bootstrapping, wherein AGTR1, age, baseline WML volume and the AGTR2-HTN interaction were present in 80% or more of the models. On examining the interaction term, the AGTR2 C allele is characterized by less change in WML volume, but only in hypertensive men. The change in WML volume was significantly different at P < 0.05 between this group (C allele, HTN present: 0.1 ml) and the other three groups (C allele, HTN absent: 1.6 ml; A allele, HTN absent: 1.6 ml; A allele, HTN present: 2.6 ml). The differences between the other three groups did not reach statistical significance. There was no significant difference in mean number of antihypertensive medications used at study entry between hypertensive men with the C allele (1.7, s.d. = 0.5, n = 9) or the A allele (2.1, s.d. = 1.4, n = 15; t = 0.80, 22 df, P = 0.4322). Analyses of the use of specific antihypertensives were not practical due to the wide range of medications.
Discussion
The primary findings relate to the AGTR1 and AGTR2 polymorphisms in men. Men homozygous for the 1166A allele exhibit significantly less change in WML volume than do 1166C allele carriers. Also, men with the AGTR2 C3123A polymorphism and HTN exhibit significantly less change in WML than men without HTN or hypertensive men with the A allele. These findings were not seen in women. We did not find any significant gene-gene or gene-diagnosis interactions.
The observed gender difference was not an a priori hypothesis. However, gender differences in blood pressure are well-documented, 23 and sex hormone influences on the RAS may be the cause. 24 RAS gene polymorphisms may have differential gender-related Abbreviation: WML, white matter hyperintense lesion. Model variables determined through backwards regression. AGTR1 genotype, depression diagnosis and hypertension were designated as variables that had to remain in the model. effects on blood pressure, 25 including effects on pulse pressure, 26 which in itself is associated with WML severity, 4 and men are more susceptible to blood pressure changes related to RAS polymorphisms. 25, 26 Presumptively, we are observing a similar phenomenon in the relationship between these polymorphisms and cerebral hyperintensities. The finding with the AGTR1 A1166C polymorphism provides new information on the relationship between this polymorphism and cerebral hyperintensities. Although not clearly replicated in a large population study examining multiple haplotypes, 27 earlier studies have associated the 1166C allele with increased risk of ischemic stroke, 7, 8, 28 whereas others associate this polymorphism with cerebrovascular disease risk factors. 7 Studies specifically examining WMLs do not present a clear picture, reporting differences, in which A1166C allele is associated with increased hyperintensity severity. 21, 28 We did not find a significant relationship between the A1166C polymorphism and WML volume at either assessment period ( Table 2 ), but did find that the genotypes exhibit different longitudinal changes in WML volume. This could reflect that the relationship between this polymorphism and WML change may be mediated by other environmental factors, such as smoking, or this polymorphism may not start affecting hyperintensity development until the time range examined in the study, beginning in the seventh decade of life. This cannot be determined in our study as we did not include midlife adult participants, nor were all environmental factors measured. Importantly, this polymorphism has an effect on hyperintensity progression, which is independent of HTN. This finding is similar to earlier observations that RAS polymorphisms, including the AGTR1 A1166C polymorphism, increased the risk of stroke independently of HTN. 29 Our finding of an interaction between AGTR2 genotype and HTN raises the study limitation that HTN was by participant self-report, and did not include blood pressure measures or current treatment. This is relevant as our finding may indicate that the 3123C allele is protective, but only in the context of specific antihypertensive treatment, as not all antihypertensives have comparable protection against cerebral ischemia. This issue is less relevant for our analyses of AGTR1, as we did not find an association between this polymorphism and HTN. Notably, others have observed an association between antihypertensive response and RAS polymorphisms, [26] [27] [28] [29] [30] but it is not clear how this relationship may affect cerebrovascular risk. Objective measures of blood pressure, along with details of antihypertensive medication use over the study period would have strengthened this hypothesis.
Our findings related to the AGTR2 polymorphism should be viewed in context of a limited sample size, in which only nine participants were male, hypertensive and AGTR2 A allele carriers. This highlights the difficulties of combining neuroimaging with genetic measures; a sample size sufficient for a neuroimaging study may be insufficient when examining multiple polymorphisms. We tested for power in this sample, comparing the nine male participants who were hypertensive and A allele carriers with the remaining 67 male participants, and using an alpha of 0.05 calculated a power of 0.23. This is low, but as lower power is associated with greater risk of a type II error or false negative rate, this does not alter the potential importance of a positive finding. It is important to note that our inability to associate C3123A with WML change in women may be accurate but also may be a false negative, as the AGTR2 polymorphism was out of Hardy-Weinberg Equilibrium in the female comparison cohort. Given these limitations, these AGTR2 C3123A findings should be viewed cautiously. However, these limitations do not apply to our analyses of the AGTR1 polymorphism, which included greater numbers and utilized the entire sample rather than dichotomizing the sample by sex.
We have focused this discussion on the relationship between these polymorphisms, HTN and WMLs. However, our findings may have other explanations, as WML progression may be affected by a number of factors, including smoking history 31 and presence of diabetes, and in the process of regulating blood pressure, angiotensin II affects salt and fluid absorption and hormone secretion, which may have independent effects. Moreover, AT 2 receptor stimulation potentiates the expression of neuroprotective factors, 6 which raises the possibility that these polymorphisms may affect cerebral tissue resilience or susceptibility to small vessel ischemia. Finally, interactions between multiple other RAS polymorphisms may pose particular risk for cerebrovascular disease. 32 As WML severity is associated with cognitive, motor and psychiatric morbidity, 1-3 it is important to better understand what factors contribute to WML development and progression, and what factors may slow or prevent WML development. Although it is difficult to definitively show that WMLs 'cause' such deficits, some longitudinal studies have shown that greater temporal increases in hyperintensity volume are associated with increased cognitive deficits 33 and poorer long-term depression outcomes. 13 WMLs are likely to be one risk factor among many for the development of such problems in the later life, along with other biological, genetic and psychosocial factors.
In conclusion, these RAS polymorphisms are associated with change in white matter hyperintensity volume in men. Further work is needed to determine how this relationship is modified by the use of specific antihypertensive medications, and whether such interventions not only slow hyperintensity progression, but also affect important clinical outcomes. Such studies may require large samples to overcome sample size issues for specific genotype combinations.
